302 related articles for article (PubMed ID: 33866536)
1. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
3. [Role of Treg/Th17 cells and related cytokines in Graves' ophthalmopathy].
Lv M; Shen J; Li Z; Zhao D; Chen Z; Wan H; Hao B
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1809-13. PubMed ID: 25537908
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
5. Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions.
Campi I; Currò N; Vannucchi G; Covelli D; Simonetta S; Fugazzola L; Dazzi D; Pignataro L; Guastella C; Lazzaroni E; Pirola G; Salvi M
Thyroid; 2021 Feb; 31(2):280-287. PubMed ID: 32940167
[No Abstract] [Full Text] [Related]
6. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.
Kim JW; Han SH; Son BJ; Rim TH; Keum KC; Yoon JS
Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):991-8. PubMed ID: 26876240
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
9. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
10. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
11. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D
Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386
[TBL] [Abstract][Full Text] [Related]
12. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
14. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
[TBL] [Abstract][Full Text] [Related]
15. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
16. What is the aim of immunosuppressive treatment in patients with graves' orbitopathy?
Yang M; Wiersinga WM; Soeters MR; Mourits MP
Ophthalmic Plast Reconstr Surg; 2014; 30(2):157-61. PubMed ID: 24492732
[TBL] [Abstract][Full Text] [Related]
17. Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy-Preliminary Results From a Prospective Single-Center Study.
Sarnat-Kucharczyk M; Świerkot M; Handzlik G; Kulawik G; Jagoda K; Grochoła-Małecka I; Fryżewska J; Mrukwa-Kominek E; Chudek J
Front Endocrinol (Lausanne); 2022; 13():871009. PubMed ID: 35615718
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
19. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
20. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
